One week after the World Health Organisation (WHO) granted Emergency Use Listing (EUL) to Covaxin, a prestigious medical journal Lancet has stated that the phase 3 data of India’s first indigenously developed vaccine demonstrates 77.8% efficacy against symptomatic Covid-19. Its efficacy data also demonstrates 70.8% protection against all variants of SARS-CoV-2.
Covaxin’s efficacy was arrived at through the evaluation of 130 confirmed cases, of which 24 were observed in the vaccine group and 106 cases were in the placebo group. The two-dose inactivated virus vaccine was developed from scratch in India by Bharat Biotech along with the Indian Council of Medical Research (ICMR) and the National Institute of Virology (NIV) Pune.
The efficacy analysis showed Covaxin (BBV152) is 93.4% effective against severe symptomatic Covid-19 and offers 63.6% protection against asymptomatic Covid-19. It is also 65.2% effective against the Delta variant, 90.1% effective against the Kappa variant, Lancet said.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.